Gevo reported a $3.7 million loss from operations for the three months ended September 30, 2025, and positive Adjusted EBITDA 1 of approximately $6.7 million for the three months ended September 30, ...

Q4 2025 Earnings Call November 10, 2025 9:00 AM ESTCompany ParticipantsJon KatholDonnie King - President, CEO & ...

Then David, who leads the Factor XI clinical program at Regeneron, will present preclinical data as well as clinical data from the ROXI-VTE-I and II studies in venous thromboembolism prevention post ...